AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, and WuXi Biologics, a global company with leading open-access biologics technology platforms, has unveiled plans to accelerate advancement of AC Immune’s TDP-43 antibody into clinical development for NeuroOrphan indications.   This next phase of the strategic partnership between the companies builds on the industry know-how of AC Immune’s proprietary drug discovery a...